What is LGD-4033 (Ligandrol)?
LGD-4033, also known as Ligandrol, is a selective androgen receptor modulator (SARM) originally developed by Ligand Pharmaceuticals and later researched by Viking Therapeutics. It was designed to selectively bind to androgen receptors in muscle and bone tissue, making it a subject of significant interest in muscle-wasting disease research.
In research models, LGD-4033 has demonstrated high anabolic activity at low doses — making it one of the most studied SARMs in published literature. It is currently being investigated as a potential treatment for osteoporosis, muscle atrophy and age-related muscle loss.
⚠ Research Purposes Only: LGD-4033 is a research chemical not approved for human consumption by the FDA or MHRA. All information on this page is for educational and research purposes only.
LGD-4033 Research Data — What the Studies Show
A Phase I clinical trial published in The Journals of Gerontology (Basaria et al., 2013) evaluated LGD-4033 in 76 healthy male volunteers. Key findings from the study:
| Dose (mg/day) | Lean Mass Gained | Duration | Suppression Noted |
|---|---|---|---|
| 0.1 mg | ~0.3 kg | 21 days | Mild |
| 0.3 mg | ~0.6 kg | 21 days | Mild–Moderate |
| 1.0 mg | ~1.2 kg | 21 days | Moderate |
All groups showed dose-dependent increases in lean body mass. The study noted that LGD-4033 was well tolerated at all doses tested with no serious adverse events reported during the 21-day period.
LGD-4033 vs RAD-140 — Research Comparison
LGD-4033 and RAD-140 are the two most researched SARMs in the USA and UK. Here's how they compare in the published literature:
| Parameter | LGD-4033 | RAD-140 |
|---|---|---|
| Human Trial Data | Phase I complete | Phase I complete |
| Anabolic:Androgenic Ratio | ~500:1 | ~90:1 (tissue selective) |
| Half-Life | 24–36 hours | 15–20 hours |
| PCT Required | Yes | Yes |
| Primary Research Focus | Muscle wasting, osteoporosis | Cancer cachexia, muscle atrophy |
Suppression & Post-Cycle Considerations in Research
The Basaria et al. trial noted dose-dependent suppression of testosterone and SHBG. This is a critical consideration for researchers — LGD-4033 does suppress the HPTA (hypothalamic-pituitary-testicular axis) in a dose-dependent manner, and recovery was observed within weeks of discontinuation in the study cohort.
Research into post-cycle therapy compounds like TUDCA is often conducted alongside LGD-4033 research protocols.
USA & UK Sourcing for LGD-4033 Research
For researchers in the USA and UK, sourcing verified LGD-4033 with third-party certificates of analysis is essential. BehemothLabz provides HPLC-tested LGD-4033 in both liquid and capsule form with batch-specific CoA documentation.
🔬 Where to Source LGD-4033 for Research (USA & UK)
For USA and UK researchers, BehemothLabz is one of the most reliable sources with third-party certificates of analysis available. All products are for research purposes only and not approved for human consumption.
Visit BehemothLabz →⚠ Affiliate link — commission earned at no extra cost. Research purposes only.
Frequently Asked Questions
LGD-4033 (Ligandrol) is being researched as a treatment for muscle-wasting conditions and osteoporosis. It is a research chemical not approved for human consumption by the FDA or MHRA.
Published research indicates LGD-4033 causes dose-dependent suppression of testosterone. Research protocols studying hormonal recovery often include post-cycle therapy compounds after LGD-4033 administration.
BehemothLabz and PureRawz are among the top-rated US vendors offering third-party tested LGD-4033 with HPLC certificates of analysis. For research purposes only.
Both have Phase I human trial data. LGD-4033 has a longer half-life (24–36 hours vs 15–20 hours for RAD-140) and a higher anabolic:androgenic ratio in preclinical models. Both are research chemicals only.